{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:25:15Z","timestamp":1787199915296,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Currently, standard therapeutic agents are not available for treating gastric intestinal metaplasia (IM). However, emerging evidence suggests the potential efficacy of metformin in addressing this issue. Our aim was to assess the efficacy and safety of metformin in reversing IM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We initially investigated the impact of metformin on reversing gastric IM in mice. An open-label, prospective, randomized controlled trial was subsequently conducted at a tertiary hospital in China from April 2022 to May 2023. A total of 140 nondiabetic patients with pathologically confirmed IM and negative\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      tests were recruited. Patients were randomly assigned at a 1:1 ratio to receive either 500 mg of metformin daily for six months or 5 mg of folate three times daily as a control. The primary outcome was defined as the regression rate of IM in different groups at the end of the treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Metformin improved gastric mucosal pathology in mice. A total of 158 patients were screened, 140 of whom were randomized to the two groups. Among these, 85\/140 (60.7%) were male, and the mean age was 55.9 \u00b1 8.3 years. Six-month follow-up data were available for 129 patients. Compared with folate users (control group), metformin users had a greater rate of regression of IM (48.6% [34\/70]\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      31.4% [22\/70]; relative risk [RR] = 1.55, 95% confidence interval [CI] 1.01\u20132.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04) in the intention-to-treat population. Furthermore, in the per-protocol population, metformin users had a higher rate of regression of IM (53.1% [34\/64]\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      33.9% [22\/65]; RR = 1.57, 95% CI 1.04\u20132.37;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). The metformin group had a low incidence of self-alleviating mild adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      This randomized clinical trial revealed that metformin can be safely administered to promote the regression of IM in nondiabetic individuals without\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, Identifier: NCT05288153.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003675","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:01:03Z","timestamp":1750032063000},"page":"2450-2458","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effect of metformin on reversing gastric intestinal metaplasia"],"prefix":"10.1097","volume":"139","author":[{"given":"Songbo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Qu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Lin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"R1-20260820","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260820","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/CM9.0000000000003277","article-title":"Burden of digestive system diseases in China and its provinces during 1990-2019: Results of the 2019 Global Disease Burden Study","volume":"137","author":"Cheng","year":"2024","journal-title":"Chin Med J"},{"key":"R3-20260820","first-page":"6735","article-title":"Human gastric carcinogenesis: A multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention","volume":"52","author":"Correa","year":"1992","journal-title":"Cancer Res"},{"key":"R4-20260820","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","article-title":"Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019","volume":"51","author":"Pimentel-Nunes","year":"2019","journal-title":"Endoscopy"},{"key":"R5-20260820","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1365-2036.2002.01300.x","article-title":"Review article: Intestinal metaplasia and gastric carcinogenesis","volume":"16","author":"Leung","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20260820","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10120-015-0462-7","article-title":"Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis","volume":"19","author":"Chen","year":"2016","journal-title":"Gastric Cancer"},{"key":"R7-20260820","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/gut.2003.034629","article-title":"Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication","volume":"53","author":"Leung","year":"2004","journal-title":"Gut"},{"key":"R8-20260820","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: A systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann Oncol"},{"key":"R9-20260820","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5009\/gnl210132","article-title":"Chemopreventive effect of metformin on gastric cancer development","volume":"16","author":"Cheung","year":"2022","journal-title":"Gut Liver"},{"key":"R10-20260820","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/gutjnl-2014-307918","article-title":"HNF4\u03b1 is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer","volume":"65","author":"Chang","year":"2016","journal-title":"Gut"},{"key":"R11-20260820","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41420-020-0290-3","article-title":"TGR5-HNF4\u03b1 axis contributes to bile acid-induced gastric intestinal metaplasia markers expression","volume":"6","author":"Ni","year":"2020","journal-title":"Cell Death Discov"},{"key":"R12-20260820","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12935-019-0739-8","article-title":"SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia","volume":"19","author":"Yuan","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R13-20260820","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10120-020-01108-x","article-title":"HDAC6\/HNF4\u03b1 loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia","volume":"24","author":"Wang","year":"2021","journal-title":"Gastric Cancer"},{"key":"R14-20260820","doi-asserted-by":"crossref","first-page":"55622","DOI":"10.18632\/oncotarget.16973","article-title":"Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: A meta-analysis of cohort studies","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"R15-20260820","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41416-021-01408-8","article-title":"Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study","volume":"125","author":"Zheng","year":"2021","journal-title":"Br J Cancer"},{"key":"R16-20260820","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.stem.2020.03.006","article-title":"A metformin-responsive metabolic pathway controls distinct steps in gastric progenitor fate decisions and maturation","volume":"26","author":"Miao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"R17-20260820","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11655-015-2114-5","article-title":"Randomized double-blind clinical trial of Moluodan for the treatment of chronic atrophic gastritis with dysplasia (in Chinese)","volume":"22","author":"Tang","year":"2016","journal-title":"Chin J Integr Med"},{"key":"R18-20260820","first-page":"731","article-title":"Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020) (in Chinese)","volume":"40","year":"2020","journal-title":"Chin J Digest"},{"key":"R19-20260820","first-page":"1317","article-title":"Precancerous gastric lesions in a population at high risk of stomach cancer","volume":"53","author":"You","year":"1993","journal-title":"Cancer Res"},{"key":"R20-20260820","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"R21-20260820","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.dld.2008.02.030","article-title":"OLGA staging for gastritis: a tutorial","volume":"40","author":"Rugge","year":"2008","journal-title":"Dig Liver Dis"},{"key":"R22-20260820","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.gie.2009.12.029","article-title":"The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis","volume":"71","author":"Capelle","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"R23-20260820","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.molmed.2012.07.006","article-title":"Gastric intestinal metaplasia revisited: Function and regulation of CDX2","volume":"18","author":"Barros","year":"2012","journal-title":"Trends Mol Med"},{"key":"R24-20260820","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/path.1928","article-title":"Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer","volume":"208","author":"Tanaka","year":"2006","journal-title":"J Pathol"},{"key":"R25-20260820","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gutjnl-2018-318025","article-title":"HNF4\u03b1 pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer","volume":"69","author":"Xu","year":"2020","journal-title":"Gut"},{"key":"R26-20260820","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1340309","article-title":"Revealing the role of metformin in gastric intestinal metaplasia treatment","volume":"15","author":"Hu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R27-20260820","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.gie.2016.03.791","article-title":"Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication","volume":"84","author":"Shichijo","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"R28-20260820","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gutjnl-2011-300154","article-title":"Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"R29-20260820","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/djy144","article-title":"Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication","volume":"111","author":"Cheung","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"R30-20260820","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1018248","article-title":"The role of the endoscopic grading of gastric intestinal metaplasia in assessing gastric cancer risk: A systematic review and meta-analysis","volume":"12","author":"Fang","year":"2022","journal-title":"Front Oncol"},{"key":"R31-20260820","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10120-018-0812-3","article-title":"The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: A systematic review and meta-analysis","volume":"21","author":"Yue","year":"2018","journal-title":"Gastric Cancer"},{"key":"R32-20260820","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:01:47Z","timestamp":1787198507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003675","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"2024-10-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}